Literature DB >> 29654146

Role of PD-1 during effector CD8 T cell differentiation.

Eunseon Ahn1, Koichi Araki1, Masao Hashimoto1, Weiyan Li1, James L Riley2,3, Jeanne Cheung4, Arlene H Sharpe5,6, Gordon J Freeman7, Bryan A Irving4, Rafi Ahmed8.   

Abstract

PD-1 (programmed cell death-1) is the central inhibitory receptor regulating CD8 T cell exhaustion during chronic viral infection and cancer. Interestingly, PD-1 is also expressed transiently by activated CD8 T cells during acute viral infection, but the role of PD-1 in modulating T cell effector differentiation and function is not well defined. To address this question, we examined the expression kinetics and role of PD-1 during acute lymphocytic choriomeningitis virus (LCMV) infection of mice. PD-1 was rapidly up-regulated in vivo upon activation of naive virus-specific CD8 T cells within 24 h after LCMV infection and in less than 4 h after peptide injection, well before any cell division had occurred. This rapid PD-1 expression by CD8 T cells was driven predominantly by antigen receptor signaling since infection with a LCMV strain with a mutation in the CD8 T cell epitope did not result in the increase of PD-1 on antigen-specific CD8 T cells. Blockade of the PD-1 pathway using anti-PD-L1 or anti-PD-1 antibodies during the early phase of acute LCMV infection increased mTOR signaling and granzyme B expression in virus-specific CD8 T cells and resulted in faster clearance of the infection. These results show that PD-1 plays an inhibitory role during the naive-to-effector CD8 T cell transition and that the PD-1 pathway can also be modulated at this stage of T cell differentiation. These findings have implications for developing therapeutic vaccination strategies in combination with PD-1 blockade.

Entities:  

Keywords:  CD8 T cells; PD-1; effector differentiation; memory cells; viral infection

Mesh:

Substances:

Year:  2018        PMID: 29654146      PMCID: PMC5939075          DOI: 10.1073/pnas.1718217115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

Review 1.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

2.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

Review 3.  Memory CD8+ T cell differentiation.

Authors:  Joshua J Obar; Leo Lefrançois
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

Review 4.  Immunological memory and protective immunity: understanding their relation.

Authors:  R Ahmed; D Gray
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection.

Authors:  Joseph N Blattman; E John Wherry; Sang-Jun Ha; Robbert G van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

9.  MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Authors:  Peter J R Ebert; Jeanne Cheung; Yagai Yang; Erin McNamara; Rebecca Hong; Marina Moskalenko; Stephen E Gould; Heather Maecker; Bryan A Irving; Jeong M Kim; Marcia Belvin; Ira Mellman
Journal:  Immunity       Date:  2016-03-02       Impact factor: 31.745

10.  Blocking of PDL-1 interaction enhances primary and secondary CD8 T cell response to herpes simplex virus-1 infection.

Authors:  Rudragouda Channappanavar; Brandon S Twardy; Susmit Suvas
Journal:  PLoS One       Date:  2012-07-12       Impact factor: 3.240

View more
  139 in total

1.  Activation and Proliferation of PD-1+ Kidney Double-Negative T Cells Is Dependent on Nonclassical MHC Proteins and IL-2.

Authors:  Mohanraj Sadasivam; Sanjeev Noel; Sul A Lee; Jing Gong; Mohamad E Allaf; Phillip Pierorazio; Hamid Rabb; Abdel Rahim A Hamad
Journal:  J Am Soc Nephrol       Date:  2019-01-08       Impact factor: 10.121

2.  An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.

Authors:  Yik Andy Yeung; Veena Krishnamoorthy; Danielle Dettling; Cesar Sommer; Kris Poulsen; Irene Ni; Amber Pham; Wei Chen; Sindy Liao-Chan; Kevin Lindquist; S Michael Chin; Allison Given Chunyk; Wenyue Hu; Barbra Sasu; Javier Chaparro-Riggers; Ivana Djuretic
Journal:  Mol Ther       Date:  2020-01-14       Impact factor: 11.454

3.  Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection.

Authors:  Thomas D Norton; Takuya Tada; Rebecca Leibowitz; Verena van der Heide; Dirk Homann; Nathaniel R Landau
Journal:  Mol Ther       Date:  2020-05-20       Impact factor: 11.454

4.  Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival.

Authors:  Derek B Danahy; Isaac J Jensen; Thomas S Griffith; Vladimir P Badovinac
Journal:  J Immunol       Date:  2019-04-10       Impact factor: 5.422

5.  Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice.

Authors:  Hao Hu; Pavel N Zakharov; Orion J Peterson; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

6.  Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.

Authors:  Derek B Danahy; Samarchith P Kurup; Christina S Winborn; Isaac J Jensen; John T Harty; Thomas S Griffith; Vladimir P Badovinac
Journal:  J Immunol       Date:  2019-06-12       Impact factor: 5.422

Review 7.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

8.  Considerations for cancer immunotherapy biomarker research during COVID-19.

Authors:  Jennifer W Carlisle; Caroline S Jansen; Mehmet Asim Bilen; Haydn Kissick
Journal:  Endocr Relat Cancer       Date:  2020-09       Impact factor: 5.678

9.  Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell-Effector Responses.

Authors:  Michael E Birnbaum; Stephanie K Dougan; Eleanor Clancy-Thompson; Christine A Devlin; Paul M Tyler; Mariah M Servos; Lestat R Ali; Katherine S Ventre; M Aladdin Bhuiyan; Patrick T Bruck
Journal:  Cancer Immunol Res       Date:  2018-10-23       Impact factor: 11.151

Review 10.  PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.

Authors:  Christopher D Nishimura; Marc C Pulanco; Wei Cui; Liming Lu; Xingxing Zang
Journal:  Trends Mol Med       Date:  2020-11-13       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.